Story preview
Continue reading on the publisher site for the full article.
Read on publisher →Kalkine Media
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
4
in the last 3 days
First reported
3 days ago
3 outlets since
Countries
3 other outlets reported this story in the last 3 days.
Gilead Sciences (NASDAQ:GILD) gets a higher price target with a neutral stance as revenue tops forecasts and shares trade near yearly highs.
Morgan Stanley dropped their price objective on shares of Gilead Sciences from $165.00 to $163.00 and set an "overweight" rating on the stock in a report on Wednesday.
Gilead Sciences (NasdaqGS:GILD) extended its AI and DevOps partnership with Cognizant through a new five-year agreement. The Cognizant deal targets broader AI integration across Gilead Sciences operations, including core business and IT functions. Gilead Sciences also expanded its oncology research collaboration with…